| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.3μM (HCV replicon); 1.9 μM (NS5B)[1]
2'-C-Methyladenosine targets the RNA-dependent RNA polymerase (NS5B) of the hepatitis C virus. The compound is converted to the active nucleoside triphosphate form within cells, which directly inhibits NS5B polymerase activity, a key enzyme for HCV genome replication. It also functions as a ribonucleoside diphosphate reductase inhibitor. |
|---|---|
| ln Vitro |
2'-C-Methyladenosine demonstrates potent in vitro antiviral activity against HCV. It inhibits HCV replicon replication with an IC50 of 0.3 μM and NS5B-catalyzed RNA synthesis with an IC50 of 1.9 μM. The compound's antiviral activity is attributed to its conversion to the active triphosphate form, which directly inhibits the viral RNA polymerase.
|
| ln Vivo |
In HB110A cells, 2'-C-Methyladenosine inhibits HCV replicons with an IC50 value of 0.3 μM [1]. NS5B-catalyzed RNA synthesis is inhibited by 2'-C-methylenedosine, with an IC50 value of 1.9 μM[1]. In Leishmania Guyana (Lgy) and Leishmania braziliensis, 2'-C-Methyladenosine efficiently inhibits LRV1 [2].
In vivo activity of 2'-C-methyladenosine has been suggested by its potent in vitro inhibition of HCV replication. The compound is a synthetic ribonucleoside analogue used in antiviral research. Further in vivo studies in appropriate animal models of HCV infection are needed to evaluate its pharmacokinetic properties, antiviral efficacy, and safety profile. |
| Enzyme Assay |
In vitro enzyme assays for 2'-C-methyladenosine involve measuring its inhibition of HCV NS5B RNA-dependent RNA polymerase activity. The assay typically uses purified recombinant NS5B polymerase and measures the incorporation of radiolabeled nucleotides into RNA in the presence of the compound. IC50 values are determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for 2'-C-methyladenosine involve treating HCV replicon-containing cells with varying concentrations of the compound and measuring viral RNA replication using qRT-PCR or luciferase reporter assays. The compound's cytotoxicity is evaluated using standard cell viability assays. IC50 values for antiviral activity are determined from dose-response curves.
|
| Animal Protocol |
In vivo animal experiments for 2'-C-methyladenosine are not extensively documented. If used in animal models of HCV infection, typical protocols would involve administering the compound to HCV-infected humanized mouse models and evaluating efficacy by measuring viral load in plasma or liver tissues. Further studies are needed to characterize its in vivo activity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2'-C-methyladenosine are limited. The compound has a molecular weight of 281.27 and a molecular formula of C11H15N5O4. Purity is ≥98%. Its absorption, distribution, metabolism, and excretion properties have not been fully characterized. The compound is a synthetic ribonucleoside analogue used in antiviral research.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2'-C-methyladenosine are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only and is not for human therapeutic application. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
2'-C-Methyladenosine (CAS#: 15397-12-3) has the molecular formula C11H15N5O4 and a molecular weight of 281.27. It is an inhibitor of HCV replication with IC50 values of 0.3 μM (replicon) and 1.9 μM (NS5B). The compound is a synthetic ribonucleoside analogue used in antiviral research. Purity is ≥98%.
|
| Molecular Formula |
C11H15N5O4
|
|---|---|
| Molecular Weight |
281.27
|
| Exact Mass |
281.112
|
| CAS # |
15397-12-3
|
| PubChem CID |
500900
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
643.4±65.0 °C at 760 mmHg
|
| Flash Point |
342.9±34.3 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.823
|
| LogP |
0.55
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
375
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)CO)O)O
|
| InChi Key |
PASOFFRBGIVJET-YRKGHMEHSA-N
|
| InChi Code |
InChI=1S/C11H15N5O4/c1-11(19)7(18)5(2-17)20-10(11)16-4-15-6-8(12)13-3-14-9(6)16/h3-5,7,10,17-19H,2H2,1H3,(H2,12,13,14)/t5-,7-,10-,11-/m1/s1
|
| Chemical Name |
(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 31.25 mg/mL (111.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5553 mL | 17.7765 mL | 35.5530 mL | |
| 5 mM | 0.7111 mL | 3.5553 mL | 7.1106 mL | |
| 10 mM | 0.3555 mL | 1.7777 mL | 3.5553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
